A novel growth hormone-releasing factor analogue, tesamorelin, provides a physiologic means of restoring a normal growth hormone secretion profile and reduces increased visceral adipose tissue, improving both abnormal lipid profiles and patients' quality of life. Glucose homeostasis is generally well maintained. Cessation of treatment with either growth hormone or tesamorelin results in a prompt return of truncal obesity. Management strategies for the long-term maintenance of the reduced visceral adipose tissue have not yet been clarified and long-term effects on decreasing cardiovascular risks and improving clinical outcomes are uncertain.Tesamorelin is a synthetic form of growth-hormone-releasing hormone which is used in the treatment of HIV-associated lipodystrophy. Tesamorelin is a synthetic peptide consisting of all 44 amino acids of hGRF with the addition of a trans-3-Hexenoic acid group.
-K602.jpg)